High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-3

  Binder, David C ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Ctla 4; Pd 1; Rescue; Salmonella; T cell; Vaccination

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; MELANOCYTE PROTEIN PMEL 17; OVALBUMIN; PROGRAMMED DEATH 1 RECEPTOR; SALMONELLA TYPHIMURIUM A1 R VACCINE; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL TRANSFER; CYTOKINE PRODUCTION; EXOME; IMMUNOSTIMULATION; MELANOMA; NONHUMAN; PROTEIN ANALYSIS; SALMONELLA TYPHIMURIUM; SEQUENCE ANALYSIS; TUMOR RESISTANCE;

EID: 84896711067     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26704     Document Type: Article

References (10)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
3. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi. org/10.1056/NEJMoa1302369
4. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi. org/10.1126/scitranslmed.3003689
5. Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, et al. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res 2013; 1:123-33; http://dx.doi. org/10.1158/2326-6066.CIR-13-0058
6. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013; 23:516-26; PMID:23597565; http://dx.doi.org/10.1016/j. ccr.2013.03.018
7. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
8. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, et al. Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. J Clin Oncol 2013; Forthcoming; PMID:24043743; http://dx.doi.org/10.1200/JCO.2012.47.7521
9. Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012; 1:409-18; PMID:22754759; http://dx.doi. org/10.4161/onci.18851
10. Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 1983; 304:165-7; PMID:6602947; http://dx.doi.org/10.1038/304165a0